Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results
|
|
- Josephine Fitzgerald
- 7 years ago
- Views:
Transcription
1 Anatomic Pathology / HPV DNA Testing in Women With Negative Cytology Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results Thomas C. Wright Jr, MD, 1 Mark H. Stoler, MD, 2 Abha Sharma, PhD, 3 Guili Zhang, PhD, 3 Catherine Behrens, MD, PhD, 3 Teresa L. Wright, MD 3 ; and the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group Key Words: Adjunct testing; Cervical cancer screening; Cervical intraepithelial neoplasia; Cytology; Genotype; HPV DNA testing; Negative for intraepithelial lesions or malignancy; NILM DOI: /AJCPTUS5EXAS6DKZ Abstract The ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV study evaluated the clinical usefulness of the cobas HPV Test (Roche Molecular Systems, Pleasanton, CA) for high-risk human papillomavirus (HR-HPV) testing (14 HR types) and individual HPV-16/HPV-18 genotyping in women undergoing routine cervical cytology screening in the United States. For the study, 47,208 women were recruited, including 32,260 women 30 years or older with negative cytology. All women with positive results for HR-HPV (n = 4,219) plus a subset of HR-HPV women (n = 886) were referred for colposcopy and biopsy. The overall prevalence of HR-HPV was 6.7% and of HPV-16/HPV-18 was 1.5%. Cervical intraepithelial neoplasia grade 2 (CIN 2) or worse was found in 1.2% of women examined. The estimated absolute risk of CIN 2 or worse in HPV-16+ and/or HPV-18+ women was 11.4% (95% confidence interval [CI], 8.4%-14.8%) compared with 6.1% (95% CI, 4.9%-7.2%) in HR-HPV+ and 0.8% (95% CI, 0.3%- 1.5%) in HR-HPV women. These analyses validate the 2006 American Society of Colposcopy and Cervical Pathology guidelines for HPV-16/HPV-18 genotyping, which recommend referral to colposcopy of HPV-16/ HPV-18+ women with negative cytology. Almost all high-grade cervical cancer precursors (cervical intraepithelial neoplasia [CIN] grades 2 and 3 [CIN 2 and 3]) and invasive cervical carcinomas are caused by persistent infection with 1 of 14 high-risk genotypes of human papillomavirus (HR-HPV). 1,2 This causal relationship has led to the introduction of sensitive molecular tests for HR-HPV into clinical practice, and testing for HR-HPV is now routinely used in the United States for managing women with mild cervical cytologic abnormalities (atypical squamous cells of undetermined significance [ASC-US]). HR-HPV testing is also used as an adjunct to cervical cytology when screening women 30 years or older. 3 However, when used for screening, the clinical usefulness of HR-HPV testing is limited by the fact that HR-HPV infections are relatively common among women without CIN 2, CIN 3, or invasive cervical cancer (CIN 2 or worse). Rather than referring all HR-HPV+ women 30 years or older with negative cytology (negative for intraepithelial lesions or malignancy [NILM]) for colposcopy, current management guidelines recommend repeating the cervical cytology and HR-HPV test in 12 months. 3 However, this conservative follow-up approach is somewhat problematic because it negates much of the benefit of the high clinical sensitivity of HR-HPV testing and can lead to a significant delay in the treatment of women with cervical cancer and a false-negative cervical cytologic result. Moreover, this strategy creates uncertainty for women who are HR-HPV+ and are deferred to follow-up rather than having information that guides immediate investigation for high-grade disease. These limitations may explain, in part, the relatively low utilization of HR-HPV testing by clinicians in the United States when screening women 30 years or older. 4,5 578 Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ
2 Anatomic Pathology / Original Article One approach to limiting the number of HR-HPV+ referrals would be to stratify (ie, triage) women with positive results for HR-HPV so that only women at greatest risk for CIN 2 or worse would undergo colposcopy and intensive follow-up. It is well recognized that among the 14 HR-HPV genotypes, HPV-16 and HPV-18 confer the greatest risk for CIN 2 or worse because these 2 genotypes are associated with approximately two thirds of all invasive cervical carcinomas. 6,7 This suggests that genotyping for HPV-16 and/or HPV-18 could be used to identify a subset of HR-HPV+ women with a particularly elevated risk of having CIN 2 or worse. Although the clinical usefulness of using genotyping for HPV-16 and/ or HPV-18 to triage HR-HPV+ women with NILM cytologic results has been recently recognized in clinical management guidelines, the data supporting the use of HPV genotyping in this manner are relatively limited. 8 The ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV study enrolled women 21 years or older undergoing routine cervical cytology screening in the United States. The trial was designed to evaluate the performance of a polymerase chain reaction based HPV assay (cobas HPV Test, Roche Molecular Systems, Pleasanton, CA) that detects 14 HR-HPV genotypes and provides 3 separate results: a pooled result for 12 HR-HPV genotypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and individual genotyping results for HPV-16 and HPV-18. Materials and Methods Study Design The ATHENA study is a prospective trial designed to evaluate the performance of a new HR-HPV test (cobas HPV Test) among women undergoing routine cervical cancer screening in the United States. The trial is being conducted in 2 phases: a baseline (cross-sectional) phase and a 3-year follow-up (longitudinal) phase that is due to be completed in December Only data from the completed crosssectional phase are reported here. The primary objective of the ATHENA study was to evaluate the performance of the cobas HPV Test in women 21 years or older with ASC-US cytology, and results are reported elsewhere. 9 Preplanned secondary objectives included a comparison of the risks of CIN 2 or worse among women 30 years or older with NILM cytology and positive for HPV-16 and/or HPV-18 with the risks for women who were positive for the 12 other HR-HPV genotypes or were HR-HPV. The current analysis is restricted to the subset of women 30 years or older with NILM cytology. The protocol was approved by the institutional review board of all study sites, and all women provided written informed consent before undergoing any study procedures. Study Population In total, 47,208 nonpregnant women 21 years or older undergoing routine cervical cancer screening were enrolled between May 2008 and August 2009 at 61 clinical centers in 23 states across the United States. Of these women, 46,887 (99.3%) met the study inclusion/exclusion criteria: intact uterus, willing to undergo colposcopy and biopsy if required, no treatment for CIN in the preceding 12 months, and no current or planned participation in a clinical trial for HPV treatment. Protocol Study Visit 1: Enrollment Visit, All Participants After informed consent and demographic and medical history were obtained, 2 liquid-based cervical cytology samples (ThinPrep, Hologic, Bedford, MA) were obtained from the cervix of each participant using a spatula and an endocervical brush. One sample was used for liquid-based cytology and for HR-HPV testing. The second liquid-based cytology sample was reserved for additional testing. Study Visit 2: Colposcopy Visit, Selected Participants Based on the results of the cervical cytology and HR-HPV testing performed on cervical samples obtained at the enrollment visit, a subset of the enrollees was selected for colposcopy as follows. Before reporting screening test results to the clinical centers, results were entered into a subject selection and randomization database that generated a list of women selected for colposcopy. This subset (n = 5,726) included all women 25 years or older with NILM cervical cytology and a positive HR-HPV test by first-generation Roche HPV tests (ie, positive for HR-HPV by the AMPLICOR HPV Test and/or LINEAR ARRAY High Risk HPV Genotyping Test [LA], Roche Molecular Systems, Pleasanton, CA) and 1,041 randomly selected women 25 years or older with NILM cytology who were negative for HPV by the AMPLICOR and LA tests. Randomization was done in a block size of 35 using SAS software, version (SAS Institute, Cary, NC). Results of the second-generation Roche HPV test (cobas HPV Test) were not used to select women for colposcopy because the test cutoff value had not been finalized at the time that enrollment into the ATHENA study was initiated. Colposcopy with biopsy and/or endocervical curettage (ECC) was performed in nonpregnant women selected for colposcopy within 12 weeks of the enrollment visit according to a standardized protocol that included biopsy of all cervical lesions and a random biopsy sample at the squamocolumnar junction in women without cervical lesions and a satisfactory colposcopy. All women with an unsatisfactory colposcopy underwent ECC. Participants and colposcopists were blinded to enrollment visit test results until the colposcopy visit was completed. Biopsies and ECCs were reviewed in a Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ 579
3 Wright et al / HPV DNA Testing in Women With Negative Cytology blinded manner by a consensus panel of 3 gynecologic pathologists and diagnosed using standard criteria and the CIN terminology, as previously described in detail. 9,10 The consensus panel diagnosis was used for all analyses. Women who underwent colposcopy and did not meet the primary study end point of histologically diagnosed CIN 2 or worse by consensus pathology were eligible for the follow-up phase (not described herein). Cytology and HR-HPV Testing Sample processing and testing were performed at 5 clinical laboratories in the United States. Two 2-mL aliquots were removed from the first liquid-based cervical cytology specimen (PreservCyt Solution, Hologic) before preparation of the cytology slide. One 2-mL aliquot was used for HR-HPV testing with first-generation HPV tests (both AMPLICOR HPV Test and LA test) according to the manufacturer s instructions. The AMPLICOR HPV Test detects 13 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; cutoff, 0.2 optical density), and the LA test detects 16 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82). The other 2-mL aliquot was tested at 1 of 5 laboratories using the second-generation HPV test (cobas HPV Test) that detects 12 pooled HR-HPV genotypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and HPV-16 and HPV-18 individually and includes a separate β-globin control. Cycle threshold cutoff values for the cobas HPV Test were established by using samples from the first approximately 29,000 women enrolled in the ATHENA study; subsequent cross-validation of the test cutoff was achieved by using samples from the remaining approximately 18,000 participants. The remainder of the liquid-based cervical cytology specimen was used to prepare a slide for cytologic evaluation (ThinPrep Pap Test, Hologic) and processed and evaluated without computerized imaging, according to the standard procedures in 4 clinical laboratories and reported using the Bethesda System. 11 Statistical Analysis Only the data for women 30 years or older with a valid NILM cytology result and valid results for all 3 HPV assays (AMPLICOR, LA, and cobas HPV Test) are included in this analysis. The absolute risks and relative risks of highgrade cervical disease with the respective 95% confidence intervals (CIs) were determined for different categories of HPV DNA result (by cobas HPV Test) in women with NILM cytology. HPV results of genotypes 16 and 18 were analyzed as individual results and as combined 16/18 results (genotype 16 and/or 18). Genotype 16+ results included cases positive for genotype 16 alone, with or without genotype 18, and with or without the 12 other HR-HPV types present. Genotype 18+ results included cases positive for genotype 18 alone, with or without a positive result for the 12 other HR-HPV genotypes, and cases negative for genotype 16. The 12 other HR-HPV+ samples were positive only for these 12 HR-HPV types. Verification bias adjusted estimates for absolute risk and relative risk in women with NILM cytology were obtained by calculating the projected number of women with and without disease who would have been found if all women had undergone colposcopy. CIs for absolute and relative risks were estimated by bootstrapping (1,000 times). 12 Results Enrollment and Demographics Among the 47,208 subjects enrolled into the trial, a total of 32,260 were 30 years or older and had valid HPV test results and an NILM cytology result at their enrollment visit. Of these women, 4,219 were classified as HR-HPV+ using the first-generation HPV tests and referred for colposcopy on that basis. An additional 886 women with NILM cytology who were HR-HPV were randomized to undergo colposcopy to adjust for verification bias Figure 1. Of the 5,105 women referred for colposcopy, 4,422 (86.6%) underwent the procedure and 4,258 (83.4%) had valid results on their cervical biopsies/ecc. Among all women referred for colposcopy, the same percentage (86.6%) from each HPV group (HPV+ and women randomized from the HPV group) completed the colposcopy visit. The mean age of the women in the NILM population included in the analysis was 44.9 years Table 1. Approximately one third were 30 to 39 years old, and 37.5% were postmenopausal. Most women (90.8%) had undergone cervical cytologic screening within the past 5 years. Prevalence of HR-HPV Among the 32,260 women 30 years or older with NILM cytology, the overall prevalence of HR-HPV (14 types) detected using the cobas HPV Test was 6.7% and the overall prevalence rates for HPV-16, HPV-18, and 12 other HR-HPV genotypes were 1.0%, 0.5%, and 5.2%, respectively Table 2. The overall prevalence of HR-HPV (14 types), as well as HPV-16 and HPV-18 individually, decreased with increasing age. Among women 50 to 59 years old, the prevalence of HR-HPV positivity was 5.3% and the prevalence of HPV-16 and HPV-18 combined was only approximately 1% (Table 2). Absolute Risks of CIN by HR-HPV Test Result Referral of HR-HPV+ women with NILM cytology was based on HPV status determined by using the first-generation HPV tests (AMPLICOR and LA tests), whereas the absolute risk of cervical disease was estimated based on the results 580 Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ
4 Anatomic Pathology / Original Article Evaluable women with NILM cytology at visit 1 (n = 32,260) Selected/randomized to visit 2 (n = 5,105) HR-HPV+* (n = 4,219) HR-HPV * (n = 886) Visit 2 colposcopy result <CIN 2 (n = 4,127) CIN 2 (n = 131) Invalid result (n = 113) No biopsy taken (n = 51) Not selected/randomized to visit 2 (n = 27,155) HR-HPV * and not randomized (n = 27,083) HR-HPV+* and error in randomization (n = 72) Exited due to loss to follow-up or other reasons (n = 683) Figure 1 Flow of evaluable women 30 years or older with NILM cytology through the study. * By Roche first-generation HPV tests. Biopsy obtained according to a standardized protocol and reviewed by central pathology review panel. Invalid biopsy result includes biopsy sample inadequate for analysis and biopsy sample obtained outside of 12-wk window. CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, high-risk; NILM, negative for intraepithelial lesions or malignancy. obtained with the second-generation cobas HPV Test. It should be noted that the AMPLICOR test is more sensitive than the cobas HPV Test from an analytic perspective, as indicated by limit of detection values expressed as cells per milliliter. 13,14 Thus, among the 4,258 women who underwent Table 1 Baseline Characteristics of Women 30 Years or Older With NILM Cytology * Evaluable Women Characteristic (N = 32,260) Age, y Mean ± SD 44.9 ± ,398 (35.3) 40 20,862 (64.7) Race White 27,197 (84.3) Black or African American 4,199 (13.0) Asian 466 (1.4) American Indian or Alaskan Native 173 (0.5) Native Hawaiian or other Pacific Islander 72 (0.2) Any combination or missing data 153 (0.5) Ethnicity Hispanic or Latino 5,736 (17.8) Postmenopausal 12,100 (37.5) HPV vaccine 45 (0.1) Immunocompromised or immunosuppressed 208 (0.6) Family history of cervical disease related to cervical cancer Yes 1,804 (5.6) No 30,133 (93.4) Unknown 323 (1.0) Previous Papanicolaou cytology test 29,301 (90.8) (within past 5 y) HPV, human papillomavirus; NILM, negative for intraepithelial lesions or malignancy. * Data are given as number (percentage) unless otherwise indicated. Evaluable women had valid HPV test results. colposcopy and had a valid biopsy result, only 1,744 women were HR-HPV+ using the cobas HPV Test and the remaining 2,514 women were HR-HPV. Of note, among women with negative results by the cobas HPV Test and who had combined AMPLICOR and LA test positive results, the crude prevalence of CIN 2 or worse was comparable with the prevalence of CIN 2 or worse for women with negative results on the AMPLICOR and LA tests (0.9% and 0.8%, respectively), thereby confirming the clinical validation of the appropriate cutoff for the cobas HPV Test. Table 2 Prevalence of HR-HPV in Women 30 Years or Older With NILM Cytology * HPV Test Result Age Group, y Total HR-HPV+ HPV-16+ HPV Other HR-HPV , , , , Overall 32, HPV, human papillomavirus; HR, high-risk; NILM, negative for intraepithelial lesions or malignancy. * HR-HPV genotypes were detected using the cobas HPV Test, and data are given as percentages. HR-HPV+ includes HPV-16+ and/or HPV-18+ and/or 12 other HR-HPV+ types; HPV-16+ includes HPV-16+, with or without HPV-18+, and with or without 12 other HR-HPV+ types; HPV-18+ includes HPV-16, HPV-18+, with or without 12 other HR-HPV+ types; 12 other HR-HPV+ include HPV-16, HPV-18, 12 other HR-HPV+ types. Evaluable women with valid HPV results and valid biopsy results. Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ 581
5 Wright et al / HPV DNA Testing in Women With Negative Cytology Based on the consensus pathology review diagnosis, the samples for 3,898 of 4,258 evaluable women who underwent colposcopy were classified as within normal limits, while 229 had biopsy-confirmed CIN 1, 51 had biopsy-confirmed CIN 2, and 80 had biopsy-confirmed CIN 3 or worse. Cases classified as CIN 3 or worse included 5 cases of adenocarcinoma in situ. Verification bias adjusted estimates of the overall absolute risk among women 30 years or older with NILM cytology at ATHENA enrollment were 1.2% (95% CI, 0.6%-1.8%) for CIN 2 or worse and 0.5% (95% CI, 0.3%-0.9%) for CIN 3 or worse Table 3. The estimated absolute risk was dependent on HR-HPV status, and HPV-16+ women had the highest absolute risks for CIN 2 or worse and CIN 3 or worse. The estimated absolute risk for CIN 3 or worse ranged from 0.3% (95% CI, 0.02%-0.7%) in women who were negative for HR-HPV to 11.7% (95% CI, 7.9%-15.8%) in women who were positive for HPV-16. Estimated absolute risks for all cobas HPV Test results stratified by age are shown in Table 3. Absolute risk in women who were HR-HPV+ showed a modest decrease with age across all combinations of results. However, the decrease in risk was more marked among women who were HPV-16+ and/or HPV-18+ compared with women who were not HPV- 16+/HPV-18+ (ie, positive for 12 other HR-HPV types). Relative Risks of CIN by HR-HPV Test Result Verification bias adjusted estimates for relative risk of CIN 2 or worse and CIN 3 or worse by HR-HPV status in women 30 years or older with NILM cytology are provided in Table 4. The relative risks for CIN 2 or worse and CIN 3 or worse were highest in women found to be HPV-16+ using the cobas HPV Test; the relative risk for CIN 2 or worse was 16.3 (95% CI, ) and for CIN 3 or worse was 42.0 (95% CI, ), compared with HR-HPV women. Furthermore, compared with HR-HPV women, the relative risks for CIN 2 or worse and CIN 3 or worse were intermediate in HPV-18+ women: 8.4 ( 95% CI, ) and 20.5 (95% CI, ), respectively. The relative risks were also intermediate in Table 4 Estimated Relative Risk of High-Grade Disease According to the HPV Test Result in Women 30 Years or Older With NILM Cytology * Table 3 Impact of HR-HPV Status on Estimated Absolute Risk of High-Grade Cervical Disease in Women With NILM Cytology * Age Group, y Estimated Relative Risk HPV Test Result CIN 2 or Worse CIN 3 or Worse HPV-16+ vs HPV 16.3 ( ) 42.0 ( ) HPV-16+/HPV-18+ vs HPV 13.7 ( ) 35.0 ( ) HR-HPV+ vs HPV 7.3 ( ) 14.4 ( ) 12 other HPV+ vs HPV 5.5 ( ) 8.7 ( ) HPV-18+ vs HPV 8.4 ( ) 20.5 ( ) HPV-16+ vs 12 other HPV+ 3.0 ( ) 4.8 ( ) CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, high-risk; NILM, negative for intraepithelial lesion or malignancy. * Relative risk was calculated using absolute risk values to 3 decimal places. HR-HPV was detected using the cobas HPV Test. Data are given as the estimated relative risk (95% CI). HR-HPV+ includes HPV-16+ and/or HPV-18+ and/or 12 other HR-HPV+ types; HPV-16+ includes HPV-16+, with or without HPV-18+, and with or without 12 other HR-HPV+ types; HPV-18+ includes HPV-16, HPV-18+, with or without 12 other HR-HPV+ types; 12 other HR-HPV+ types include HPV-16, HPV-18, 12 other HR-HPV+ types. HPV Test Result Overall CIN 2 or worse HR-HPV+ 8.4 ( ) 5.4 ( ) 1.3 ( ) 5.4 ( ) 6.1 ( ) HPV-16+/HPV ( ) 7.4 ( ) 4.4 ( ) 0.0 ( ) 11.4 ( ) HPV ( ) 10.0 ( ) 2.4 ( ) 0.0 ( ) 13.6 ( ) HPV ( ) 2.4 ( ) 3.7 ( ) 0.0 ( ) 7.0 ( ) 12 other HR-HPV+ 5.6 ( ) 4.9 ( ) 0.6 ( ) 6.6 ( ) 4.6 ( ) HR-HPV 0.1 ( ) 0.8 ( ) 1.2 ( ) 3.1 ( ) 0.8 ( ) Overall 1.2 ( ) CIN 3 or worse HR-HPV+ 5.7 ( ) 3.5 ( ) 1.1 ( ) 2.7 ( ) 4.1 ( ) HPV-16+/HPV ( ) 6.6 ( ) 4.4 ( ) 0.0 ( ) 9.8 ( ) HPV ( ) 7.5 ( ) 2.4 ( ) 0.0 ( ) 11.7 ( ) HPV ( ) 2.4 ( ) 3.7 ( ) 0.0 ( ) 5.7 ( ) 12 other HR-HPV+ 3.0 ( ) 2.8 ( ) 0.3 ( ) 3.3 ( ) 2.4 ( ) HR-HPV 0.0 ( ) 0.4 ( ) 0.0 ( ) 1.6 ( ) 0.3 ( ) Overall 0.5 ( ) CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, high-risk; NILM, negative for intraepithelial lesion or malignancy. * Estimated absolute risk is the number of subjects with disease/number of subjects with positive test results adjusted for verification bias. HR-HPV was detected using the cobas HPV Test, and data are given as the estimated absolute risk (95% CI) in percentages. HR-HPV+ includes HPV-16+ and/or HPV-18+ and/or 12 other HR-HPV+ types; HPV-16+ includes HPV-16+, with or without HPV-18+, and with or without 12 other HR-HPV+ types; HPV-18+ includes HPV-16, HPV-18+, with or without 12 other HR-HPV+ types; 12 other HR-HPV+ types include HPV-16, HPV-18, 12 other HR-HPV+ types. Data for subjects 70 years or older with NILM cytology are not included in this table because no CIN 2 or worse was diagnosed in this age group. 582 Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ
6 Anatomic Pathology / Original Article women with positive results for 12 other HR-HPV types: 5.5 (95% CI, ) and 8.7 (95% CI, ), respectively. Discussion The ATHENA study is the first trial to evaluate the clinical usefulness of HR-HPV DNA testing and HPV- 16/HPV-18 genotyping among a large cohort of women undergoing routine cervical cytologic screening in the United States. The current analysis focused on women 30 years or older with NILM cytology results. The main findings are that the absolute and relative risks of CIN 2 or worse and CIN 3 or worse in women with NILM cytology are impacted not only by HR-HPV (14 types) status, but even more so by whether HPV-16 or HPV-18 is detected. Prior cross-sectional and prospective studies have clearly demonstrated that HR-HPV status is an important predictor of the current and future detection of CIN 2 or worse in women with NILM cytology. Based on this finding, current US cervical cancer screening guidelines recommend extending the screening interval to at least 3 years in women 30 years or older with NILM cytology who are HR-HPV and retesting women who are HR-HPV+ at 12 months using cervical cytology and HPV tests. Women who are HPV with low-grade squamous intraepithelial lesions or greater on the repeated cytology and women who are persistently HR-HPV+ should be referred for colposcopy. 3 Therefore, it is not unexpected that in the current analysis, HR-HPV status had a marked impact on the risks of CIN 2 or worse and CIN 3 or worse in women 30 years or older with NILM cytology; however, data have not been previously reported for HPV-16/HPV-18. In women with NILM cytology who were also HR-HPV+ (14 types), the estimated absolute risk of CIN 3 or worse at baseline was 4.1% (95% CI, 3.1%-5.0%), and the relative risk of CIN 3 or worse was 14.4 (95% CI, ) compared with women who were HR-HPV. The presence of HPV-16 or HPV-18 in women 30 years or older with NILM cytology was found to greatly magnify the risk of CIN 3 or worse, as did the presence of HPV-16 alone. The absolute risk for CIN 3 or worse in women with NILM cytology who were HPV-16+ was 11.7% (95% CI, 7.9%-15.8%); the relative risk of CIN 3 or worse compared with women who were HR-HPV (14 types) was 42.0 (95% CI, ). The absolute risk in women who were HR-HPV+ showed a modest decrease with age across all combinations of results, and the decrease was more marked among women who were HPV-16+ and/or HPV-18+ compared with women who were not HPV-16+/HPV-18+ (ie, positive for 12 other HR-HPV types). The decrease in risk of high-grade disease is consistent with the reported peak age of CIN 3 in the United States (25-29 years) 21 and was also observed in the overall population of the ATHENA trial. 22 Two prospective follow-up studies have shown the importance of HPV-16 in predicting the women with NILM cytology in whom high-grade CIN will develop. In the study by Khan et al, 23 in women enrolled in the Kaiser Permanente health management organization (Portland, OR), the 10-year cumulative incidence rate (CIR) of CIN 3 or worse in women 30 years or older with NILM cytology at enrollment was 20.7% (95% CI, 8.6%-32.8%) among HPV-16+ women and 17.7% (95% CI, 0.0%-36.0%) among HPV-18+ women. In contrast, the 10-year CIR of CIN 3 or worse was only 1.5% (95% CI, 0.3%-2.7%) among HR-HPV+ women who were negative for both HPV-16 and HPV In the Kaiser study, the increased detection of CIN 3 or worse in women who were HPV-18+ was delayed by approximately 2 years compared with the increase seen in women who were HPV A 2-year delay in the oncogenic effects of HPV-18 compared with HPV-16 could explain the somewhat lower impact of HPV-18 compared with HPV-16 observed in the current cross-sectional analysis of the ATHENA trial. Similar data have recently been reported from a Danish prospective follow-up study. After a 12-year follow-up, the estimated probability of developing CIN 3 or worse in HPV-16+ women with NILM cytology was 26.7% (95% CI, 21.1%-31.8%), and for HPV-18+ women, it was 19.1% (95% CI, 10.4%-27.3%). In contrast with the Kaiser study, an increased risk similar to that associated with HPV-18 was also found in women who were positive for HPV-31 and HPV-33. Women with an HR-HPV other than types 16, 18, 31, or 33 had a relatively lower absolute risk of CIN 3 (6.0% [95% CI, 3.8%-8.3%]). 20 In the current analysis, the verification bias adjusted absolute risks of CIN 2 or worse and of CIN 3 or worse in women 30 years or older with NILM cytology were 1.2% (95% CI, 0.6%-1.8%) and 0.5% (95% CI, 0.3%- 0.9%), respectively. Based on older data, this finding seems somewhat high, especially given that liquid-based cytology was used for screening in the ATHENA study and that only women 30 years or older are included in the current analysis. For example, a retrospective study of 128,805 women with NILM cytology enrolled in the National Breast and Cervical Cancer Early Detection Program found that the age-adjusted incidence rate of having a cervical cytology result of highgrade squamous intraepithelial lesions or worse within 3 years of the initial negative cytology was only approximately 0.2%. 24 However, more recent studies that have performed colposcopy in women with abnormal cytology and women who are HR-HPV+ have found a higher prevalence of highgrade CIN in women with NILM cytology. 18,25,26 A comprehensive review of 7 prospective European screening trials found that after 3 years of follow-up, the CIR of CIN 2 or worse in women with NILM cytology was 0.8% (95% CI, 0.4%-1.2%) and the CIR of CIN 3 or Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ 583
7 Wright et al / HPV DNA Testing in Women With Negative Cytology worse was 0.5% (95% CI, 0.2%-0.8%). 18 North American screening studies that have not only performed colposcopy on HR-HPV+ women, but also adjusted for verification bias by performing colposcopy in a subset of women with negative screening test results, report absolute risks of high-grade CIN in women with NILM cytology that are both higher and lower than found in the ATHENA study. Kulasingam et al 25 used 2 different HR-HPV tests and liquid-based cytology to screen more than 4,000 women visiting Planned Parenthood clinics in Washington State. After adjusting for verification bias, the absolute risk of CIN 3 or worse was approximately 1.5% (calculated from data in Figure 2 in their article) in women of all ages with an NILM liquid-based cytology result. 25 Another study of similar design that used conventional cytology screened more than 10,000 Canadian women 30 years or older. In this study, the verification bias adjusted prevalence of CIN 2 or worse was 0.8% (calculated from data in Figure 1 in their article) in women 30 years or older with an NILM cytology result, which is similar to the 1.2% found in the current analysis. 26 There is considerable controversy as to the merits of adjusting for verification bias. In general, the proportion of women with negative results by both HPV testing and cervical cytology who undergo colposcopy in studies that adjust for verification bias is low, and, therefore, attempts to adjust for missed disease in this group tend to lead to magnification of these few cases. 27 Moreover, relatively few cases of highgrade CIN are identified in women who are both HPV and cytology negative, and this can also lead to unstable results. 16 Adjustment for verification bias may explain why the absolute risk of CIN 2 or worse in women who had NILM cytology and tested HR-HPV (14 types) was 0.8% (95% CI, 0.3%- 1.5%) in the current analysis. This rate is considerably higher than the expected rate of 1 in 1, The present study has a number of considerable strengths. These strengths include the large number of women who were evaluated, the fact that all women enrolled had both cytology and HPV testing performed, that liquid-based cytology was used, and that all cervical cytology was evaluated in 4 different laboratories under routine practice conditions. In addition, all colposcopy examinations and evaluations of samples were performed without knowledge of clinical information or the results of other laboratory tests, a standardized approach was taken to colposcopy with a biopsy of normal-appearing cervix obtained in women without visible cervical lesions at the time of colposcopy, and adjudicated pathology was used to determine the gold standard. This study clearly defines risk for disease at baseline in women 30 years or older undergoing routine cervical cancer screening in the United States who are found to have an NILM cytology result. Risk for high-grade neoplasia is greatly elevated in HPV-16+/HPV-18+ women and is further increased when restricted to HPV-16 alone. Risk associated with HPV-16+/HPV-18 is considerably greater than the risk associated with the 12 other HR-HPV genotypes. Moreover, the absolute risk for CIN 3 or worse in HPV-16+/HPV-18+ women 30 years or older with NILM in the ATHENA study (9.8%) is approximately the same as for women 21 years or older with ASC-US who are HR-HPV+ (14 pooled types) in the ATHENA study (8.4%). 9 Based on rather limited data, predominantly from the study by Khan et al, 23 the 2006 American Society of Colposcopy and Cervical Pathology Consensus Conference approved a strategy incorporating HPV-16/HPV-18 genotyping when managing women 30 years or older undergoing routine cervical cancer screening and found to be HR-HPV+ with NILM cytology. With this strategy, HPV- 16+/HPV-18+ women with NILM cytology are referred for immediate colposcopy, whereas women who are positive for the 12 other HR-HPV genotypes undergo repeated testing with both cytology and HR-HPV testing at 12 months. 8 While the risk threshold for performing colposcopy in response to specific cytology and HPV test results is still being defined, Castle et al 29 suggested that women with an absolute risk for CIN 3 or worse of 10% or more over 2 years should undergo colposcopy. Because the present study indicates that the risk of an HPV-16+ and/or HPV-18+ woman with NILM cytology having CIN 3 or worse is 9.8% at baseline, these data clearly support the recommendation for immediate referral to colposcopy in accordance with the 2006 American Society of Colposcopy and Cervical Pathology guidelines for HPV-16/HPV-18 genotyping of women with NILM cytology. From the 1 Department of Pathology, Columbia University School of Medicine, New York, NY; 2 University of Virginia Health System, Charlottesville; and 3 Roche Molecular Systems, Pleasanton, CA. Funded by Roche Molecular Systems, Pleasanton, CA. Address reprint requests to Dr Behrens: Roche Molecular Systems, 4300 Hacienda Dr, Pleasanton, CA Disclosure: Dr T.C. Wright has been a consultant and speaker for Merck, GlaxoSmithKline, and Roche Diagnostics and a consultant for Gen-Probe. Dr Stoler has been a consultant in clinical trial and HPV DNA test development for Third Wave, Hologic, QIAGEN, Roche Molecular Systems, and Gen-Probe. Drs Sharma, Zhang, Behrens, and T.L. Wright are employed by Roche Molecular Systems, the sponsor of the study. Acknowledgment: Editorial assistance was provided by Health Interactions, London, England. The ATHENA Central Pathology Review Panel includes Thomas C. Wright Jr, MD, Department of Pathology, Columbia University School of Medicine, NY; Mark H. Stoler, MD, University of Virginia Health System, Charlottesville; and Alexander Ferenczy, MD, Department of Pathology, McGill University, Montreal, Canada. The ATHENA study testing sites and participants are as follows: 584 Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ
8 Anatomic Pathology / Original Article Laboratory testing sites: B.A. Body, LabCorp, Burlington, NC; A. Butcher, Roche Molecular Systems, Pleasanton, CA; C. Eisenhut, DCL Medical Laboratories, Indianapolis, IN; A. Rao, Scott & White Memorial, Temple, TX; and S. Young, TriCore Reference Laboratories, Albuquerque, NM. Collection sites (principal investigators and institutions): R. Ackerman, Comprehensive Clinical Trials, West Palm Beach, FL; R. Anders, Green Clinic, Ruston, LA; E. Andruczyk, Philadelphia Clinical Research, Philadelphia, PA; K. Aqua, Visions Clinical Research, Boynton Beach, FL; R. Black, Women s Health Specialist, Costa Mesa, CA; S. Blank, Mount Vernon Clinical Research, Atlanta, GA; P. Bressman, Tennessee Women s Care, Nashville, TN; K. Brody, Chattanooga Medical Research, Chattanooga, TN; J. Burigo, OB/GYN Specialists of the Palm Beaches, West Palm Beach, FL; S. Chavoustie, Segal Institute for Clinical Research, North Miami, FL; M. Davis, SC Clinical Research Center, Columbia, SC; A. Donovan, Bluegrass Clinical Research, Louisville, KY; S. Eder, Delaware Valley OB-GYN and Infertility Group, Plainsboro, NJ; C. Eubank, Advanced Research Associates, Corpus Christi, TX; S. Fehnel, Advanced Clinical Concepts, West Reading, PA; R. Feldman, Miami Research Associates, Miami, FL; R. Filosa, Center for Women s Health of Lansdale, Lansdale, PA; S. Fowler, Blue Skies Center for Women, Colorado Springs, CO; C. Goldberg, Visions Clinical Research, Tucson, AZ; R. Groom, Impact Clinical Trials, Las Vegas, NV; J. Grube, Physicians Research Options, Lakewood, CO; P. Grumley, Four Rivers Clinical Research, Paducah, KY; P. Hadley, Medical Network for Education and Research, Decatur, GA; M. Harris, Women s Health Research, Phoenix, AZ; L. Hazan, Impact Clinical Trials, Los Angeles, CA; J. Huey, HWC Women s Research Center, Englewood, OH; M. Jacobs, Texas Medical Center, Houston; S. Kleinpeter, Mobile OB/GYN, Mobile, AL; S. Lederman, Altus Research, Lake Worth, FL; J. Lenihan Jr, Tacoma Women s Specialist, Tacoma, WA; B. Levine, Phoenix OB-GYN Association, Moorestown, NJ; K. Lowder, The Woman s Clinic, Boise, ID; N. Lurvey, Impact Clinical Trials, Los Angeles, CA; J. Martin Jr, ecast Corporation, North Charleston, SC; R. McDavid, State of Franklin Healthcare Associates Research, Johnson City, TN; J. McGettigan, Quality of Life Medical & Research Center, Tucson, AZ; J. Michelson, Eastern Carolina Women s Center, New Bern, NC; F. Morgan, Tidewater Clinical Research, Virginia Beach, VA; R. Myers, St John s Center for Clinical Research, Jacksonville, FL; K. Osman, M & O Clinical Research, Ft Lauderdale, FL; R. Parker Jr, Lyndhurst Gynecologic Associates, PA, Winston- Salem, NC; J. Pollard, Enterprise Women s Center, Enterprise, AL; A. Rappleye, Salt Lake Research, Salt Lake City, UT; R. Reagan, Women s Health Care at Frost Street, San Diego, CA; H. Reisman, Atlanta North Gynecology Center for Research, Roswell, GA; L. Rogers, Women s Clinical Research, Newburgh, IN; N. Sager, Jacksonville Center for Clinical Research, Jacksonville, FL; G. Sieggreen, Women s OB-GYN, Saginaw, MI; W. Somerall Jr, Clinical Research Consultants, Hoover, AL; M. Sperling, Edinger Medical Group Research Center, Fountain Valley, CA; R. Surowitz, Health Awareness, Jupiter, FL; M. Swor, Physician Care Clinical Research, Sarasota, FL; S. Trupin, Woman s Health Practice, Champaign, IL; A. Tydings, Clinical Trials Management, Covington, LA; K. Waldrep, Advanced Research Associates, Dallas, TX; D. Walland, Fellows Research Alliance, Savannah, GA; D. Walland, Fellows Research Alliance, Hilton Head, SC; W. Wilkerson, Women s Care Florida, Tampa; W. Wilson, Advanced Research Associates, McAllen, TX; S. Wininger, Precision Trials, Phoenix, AZ; and S. Yassear, Yassear Clinical Research, Carmichael, CA. References 1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189: Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370: Wright TC Jr, Massad LS, Dunton CJ, et al consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197: Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010;170: Saraiya M, Irwin KL, Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer. 2007;110: Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr. 2003: de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7: American Society for Colposcopy and Cervical Pathology HPV Genotyping Clinical Update org/consensus.shtml. Accessed February Stoler MH, Wright TC Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135: Kurman RJ, Ellenson LH, Bonnett BM. Blaustein s Pathology of the Female Genital Tract. New York, NY: Springer Verlag; Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287: Chernick M. Bootstrapping Methods: A Practitioner s Guide. New York, NY: Wiley Interscience; 1999:8, cobas HPV Test [package insert]. Pleasanton, CA: Roche Molecular Systems; The AMPLICOR Human Papillomavirus (HPV) test [package insert]. Pleasanton, CA: Roche Molecular Systems; Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer. 2005;93: Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119: Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ 585
9 Wright et al / HPV DNA Testing in Women With Negative Cytology 17. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98: Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. doi: /bmj.a Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial [published online ahead of print February 18, 2011]. Eur J Cancer. doi: /j. ejca Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102: Moscicki AM, Schiffman M, Kjaer S, et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(suppl 3):S3/42-S3/ Wright TC Jr, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. In press. 23. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97: Sawaya GF, Kerlikowske K, Lee NC, et al. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol. 2000;96: Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288: Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357: Sasieni P. Estimating prevalence when the true disease status is incompletely ascertained. Stat Med. 2001;20: Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103: Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.e1-356.e6. doi: /j.ajog Am J Clin Pathol 2011;136: DOI: /AJCPTUS5EXAS6DKZ
HUMAN PAPILLOMAVIRUS (HPV) TESTING
MEDICAL POLICY HUMAN PAPILLOMAVIRUS (HPV) TESTING Policy Number: CDP - 041 Effective Date: October 1, 2014 Table of Contents Page BACKGROUND 1 POLICY 3 REFERENCES 5 POLICY HISTORY/REVISION HISTORY 7 INSTRUCTIONS
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationNATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME
NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME CERVICAL CANCER Introduction Cancer of the cervix is the second most common form of cancer amongst South African women. Approximately one in every
More informationCervical Cancer Screening Guideline
Cervical Cancer Screening Guideline Prevention 2 Abbreviations Used 2 Specimen Collection Techniques 3 Screening 4 Management Women 21 Years and Older Pap results 5 findings: ASC-US and LSIL 6 findings:
More informationGUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015
GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015 Cervical cancer remains an important cause of morbidity and mortality in South Africa. At present the national cervical cancer prevention
More informationHPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer
Revolutionizing healthcare one cell at a time HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer Numerous studies confirm that the presence of HR HPV DNA
More informationExplanation of your PAP smear
Explanation of your PAP smear Approximately 5-10% of PAP smears in the United States are judged to be abnormal. Too often, the woman who receives this news worries that she already has, or will develop,
More informationManagement of Abnormal Pap Smear Clinical Practice Guideline
Management of Abnormal Pap Smear Clinical Guideline General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method
More informationManagement of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference
Management of Abnormal PAP Smears K Chacko, MD, FACP 2010 GIM Conference Scope of the Problem About 7-10% 7 of PAPs will come back abnormal 3.5 to 4 million in the US each year Approximate 4000 deaths
More informationGLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET
GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET When detected, HPV infection is easily managed and rarely proceeds to cancer Very few women with HPV develop cervical cancer HPV infections are only one of
More informationCervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women
QEYGYN051 Cervical Cancer Screening Clinical Practice Guidelines for Average Risk Women For Approval of the Provincial Medical Affairs Committee October 2013 Table of Contents Page Background Information
More informationCervical Cancer Screening and Management Guidelines: Changing Again, Huh?
Cervical Cancer Screening and Management Guidelines: Changing Again, Huh? Summary of 2013 recommendations from ASC (American Cancer Society), ASCCP (American Society for Colposcopy and Cervical Pathology),
More informationCXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics. www.gbo.
CXCA-MSP The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics www.gbo.com/diagnostics H 3 C NH 2 NH H 3 C 2 N mc N mc N H N O H O The challenge of
More informationThe Cervical Screening Manual
The Cervical Screening Manual A Guide for Health Departments and Providers Collaboration Partners: Chronic Disease and Injury Section Breast and Cervical Cancer Control Program Women s and Children s Health
More informationTesting for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology
67 Testing for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology Positive Rates in Equivocal and Abnormal Specimens and Comparison With the ASCUS to SIL Ratio Vincent Ko, MD Shabin
More informationHPV and the Future of Cervical Screening
HPV and the Future of Cervical Screening John Tidy, Professor of Gynaecological Oncology Chair, National Colposcopy QA Committee, Sheffield What is HPV? Small ds DNA virus Over 140 genotypes described
More informationCervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University
Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University Burden of HPV related cancers l l Cervical Cancer of the cervix
More informationAbnormal Pap Smear Tracking in General Internal Medicine Clinic
Abnormal Pap Smear Tracking in General Internal Medicine Clinic J A C O B K U R L A N D E R & T A R A O B R I E N C A R Q I P R O J E C T J A N U A R Y 2 0, 2 0 1 0 PDSA cycle Plan Act Do Study Our Charge
More informationDr Julia Palmer BAC Annual Scientific Meeting October 2015 THE IMPACT OF HPV PRIMARY SCREENING ON COLPOSCOPY.
Dr Julia Palmer BAC Annual Scientific Meeting October 2015 THE IMPACT OF HPV PRIMARY SCREENING ON COLPOSCOPY. Aims: An evaluation of primary HPV screening commenced in Sheffield in May 2013. This lecture
More information2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors
2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors L. Stewart Massad, MD, Mark H. Einstein, MD, Warner K. Huh, MD, Hormuzd A. Katki,
More informationPap smears, cytology and CCHC lab work and follow up
Pap smears, cytology and CCHC lab work and follow up What is a Pap Smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the
More informationHPV testing in the follow-up of women post colposcopy treatment
HPV testing in the follow-up of women post colposcopy treatment Contents Background 2 Treatment of CIN and risk of recurrence 2 The natural history of HPV infections 2 HPV testing for women following
More informationAmerican Academy of Family Physicians
American Academy of Family Physicians Barbara E. Stanford MD Grand Rapids Family Medicine Residency Wege Family Medicine HPV is transient in most women HPV-75% Normal ASCUS LSIL HSIL Cancer 80-90% 75%???
More informationMedia Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com
News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com Merck's HPV Vaccine, GARDASIL 9, now available
More informationHealth Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January June 2013
Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January June 2013 by Michael E. Martinez, M.P.H., M.H.S.A., and Robin A. Cohen, Ph.D. Division of Health
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationAPPENDIX 1: SURVEY. Copyright 2010 Major, Lindsey & Africa, LLC. All rights reserved.
APPENDIX 1: SURVEY Major, Lindsey & Africa Partner Compensation Survey (2010) Dear : Major, Lindsey & Africa invites you to participate in our 2010 MLA Partner Compensation Survey. This Survey, which is
More informationThe Youth Vote in 2012 CIRCLE Staff May 10, 2013
The Youth Vote in 2012 CIRCLE Staff May 10, 2013 In the 2012 elections, young voters (under age 30) chose Barack Obama over Mitt Romney by 60%- 37%, a 23-point margin, according to the National Exit Polls.
More informationGrantee City State Award. Maricopa County Phoenix AZ $749,999. Colorado Youth Matter Denver CO $749,900
OAH TEEN PREGNANCY PREVENTION PROGRAM GRANTS July 2015 Capacity Building to Support Replication of Evidence-Based TPP Programs (Tier 1A) Grantee City State Award Maricopa County Phoenix AZ $749,999 Colorado
More informationColposcopic Management of Abnormal Cervical Cytology and Histology
No. 284, December 2012 Colposcopic Management of Abnormal Cervical Cytology and Histology This clinical practice guideline has been prepared by the Executive Council of the Society of Canadian Colposcopists
More informationNational Bureau for Academic Accreditation And Education Quality Assurance PUBLIC HEALTH
1 GEORGE WASHINGTON UNIVERSITY WASHINGTON DC B Athletic Training 1 MA B 1 BROWN UNIVERSITY PROVIDENCE RI B EAST TENNESSEE STATE UNIVERSITY JOHNSON CITY TN B 3 HUNTER COLLEGE NEW YORK NY B 4 UNIVERSITY
More informationSage Screening Program. Provider Manual
Sage Screening Program Provider Manual Sage Screening Program Minnesota Department of Health 85 E. 7th Place, Suite 400 P.O. Box 64882 St. Paul, Minnesota 55164-0882 (651) 201-5600 (phone) (651) 201-5601-
More informationCervical Cancer The Importance of Cervical Screening and Vaccination
Cervical Cancer The Importance of Cervical Screening and Vaccination Cancer Cells Cancer begins in cells, the building blocks that make up tissues. Tissues make up the organs of the body. Sometimes, this
More informationGenital Human Papillomavirus. Patti E. Gravitt, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationCancer of the Cervix
Cancer of the Cervix WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 A woman's cervix (the opening of the uterus) is lined with cells. Cancer of the cervix occurs when those cells change,
More informationPhysical Therapy Marketing Success :: physical therapy assistant schools usa
Physical Therapy Marketing Success :: physical therapy assistant schools usa Physical Therapy Marketing Success :: physical therapy assistant schools usa Downloading From Original Website --> http://f-ebook.esy.es/ptsuccess/pdx/fph1
More informationPROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor
1 ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor Cervical cytology screening has significantly decreased rates of mortality from cervical cancer; however, 400 women die each year
More informationChallenges and Progress: Implementing HIV Screening in Health-Care Settings
Challenges and Progress: Implementing HIV Screening in Health-Care Settings Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS,
More informationInitial Accreditation
The following Final Actions were taken by the CCNE Board of Commissioners at its meeting on April 22-25, 2014. UPDATED - June 24, 2014 Initial Accreditation Accredited Program(s) Accreditation Term Expires
More informationHPV DNA-Chip. PapilloCheck HPV-Screening. DNA-Chip for the genotyping of 24 types of genital HPV
HPV DNA-Chip PapilloCheck HPV-Screening DNA-Chip for the genotyping of 24 types of genital HPV PapilloCheck : fast and reliable PapilloCheck at a glance: Complete kit with DNA-arrays and solutions for
More informationDepartment of Veterans Affairs Quarterly Notice to Congress on Data Breaches Third Quarter of Fiscal Year 2015 April 1, 2015 through June 30, 2015
VHA 4/1/15 VISN 01 Boston, MA 1 0 4/15/15 VISN 01 Boston, MA 1 0 4/22/15 VISN 01 Boston, MA 10 0 4/24/15 VISN 01 Boston, MA 1 0 4/27/15 VISN 01 Boston, MA 0 1 4/29/15 VISN 01 Boston, MA 0 1 4/30/15 VISN
More informationXI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012
XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome 19-21 April 2012 Thursday 19 nd April 2012 Morning Sessions 07.50-08.20 Registration 08.20-08.40 Welcome:
More informationHealth Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, 2013
Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, 2013 by Robin A. Cohen, Ph.D., and Michael E. Martinez, M.P.H., M.H.S.A. Division of Health Interview Statistics,
More information92-0200. An in vitro diagnostic test for the detection of DNA from Human Papillomavirus (HPV) Type 16 and Type 18 in Cervical Specimens.
Cervista HPV 16/18 92-0200 An in vitro diagnostic test for the detection of DNA from Human Papillomavirus (HPV) Type 16 and Type 18 in Cervical Specimens. -30 C -15 C In vitro diagnostic medical device
More information2011 Match List. Riverside Country Regional Medical Center. Virginia Mason Medical Center WA. Good Samaritan Hosp and Medical Center, NY
2011 Match List Program Diagnostic Radiology Diagnostic Radiology /NMM Institution Riverside County Regional Medical Center Riverside Country Regional Medical Center Detroit Medical Center Cleveland Clinic
More informationNumber of Liver Transplants Performed 2003-2004 Updated October 2005
PEDIATRIC CENTERS PEDIATRIC TRANSPLANT CENTERS Number of Liver Transplants Performed 2003-2004 Updated October 2005 University of Alabama Hospital, Birmingham, AL 3 2 1 University Medical Center, University
More informationThe Most Affordable Cities For Individuals to Buy Health Insurance
The Most Affordable Cities For Individuals to Buy Health Insurance Focusing on Health Insurance Solutions for Millions of Americans Copyright 2005, ehealthinsurance. All rights reserved. Introduction:
More informationColorectal Cancer Screening Behaviors among American Indians in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University
More informationFMLA AMENDED TO PROVIDE LEAVE TO
EMPLOYEE BENEFITS ALERT February 2008 Issue 126 FMLA AMENDED TO PROVIDE LEAVE TO MILITARY FAMILIES The Family and Medical Leave Act (FMLA) now grants FMLA leave rights in two additional circumstances that
More informationNYCOM 2009 Entering Class - Matriculant Comparison Data
NYCOM 2009 Entering Class - Matriculant Comparison Data Enclosed are summary tables of the 2009 matriculants and parallel data for matriculants to your college. Matriculant data were matched to the applicant
More informationAll Students Two-year Colleges Number of Students Tested at Each Institution July 2008 through June 2013
Number of Students Tested at Each Institution July 2008 through June 2013 List of Institutions Number of School Name Students AIKEN TECHNICAL COLLEGE, SC 391 ARKANSAS NORTHEASTERN COLLEGE, AR 150 ASHLAND
More informationHUMAN PAPILLOMAVIRUS (HPV) FACT SHEET
HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET Background Information - Human Papillomavirus HPV is the name of a group of viruses that include more than 80 different types associated with a variety of epidermal
More informationPhysical Therapy Marketing Success :: physical therapy assistant schools usa
Physical Therapy Marketing Success :: physical therapy assistant schools usa Physical Therapy Marketing Success :: physical therapy assistant schools usa Downloading From Original Website --> http://f-ebook.esy.es/ptsuccess/pdx/fph1
More informationCervical cancer screening: What s new and what s coming?
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will adhere to current guidelines for screening for cervical cancer Xian Wen Jin, MD, PhD, FACP* Department of Internal Medicine, Cleveland Clinic; Assistant
More informationADEA Survey of Dental School Seniors, 2014 Graduating Class Tables Report
ADEA Survey of Dental School Seniors, 2014 Graduating Class Tables Report Published February 2015 Suggested Citation American Dental Education Association. (February 2015). ADEA Survey of Dental School
More informationALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL
ALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL Revised January 2012 1 TABLE OF CONTENTS PROGRAM OVERVIEW.. 3 INTRODUCTION 5 SCREENING ELIGIBILITY GUIDELINES 6 PATIENT RIGHTS..
More informationFact Sheet URBAN INSTITUTE. Where Do Gay and Lesbian Couples Live?
Where Do Gay and Lesbian Couples Live? Census 2000 counts same-sex couples in 99 percent of U.S. counties. Like the distribution of the U.S. population at large, the distribution of gay and lesbian families
More informationMapping State Proficiency Standards Onto the NAEP Scales:
Mapping State Proficiency Standards Onto the NAEP Scales: Variation and Change in State Standards for Reading and Mathematics, 2005 2009 NCES 2011-458 U.S. DEPARTMENT OF EDUCATION Contents 1 Executive
More informationThe MetLife Market Survey of Assisted Living Costs
The MetLife Market Survey of Assisted Living Costs October 2005 MetLife Mature Market Institute The MetLife Mature Market Institute is the company s information and policy resource center on issues related
More informationHow To Calculate Health Insurance Coverage In The United States
Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January March 2014 by Robin A. Cohen, Ph.D., and Michael E. Martinez, M.P.H., M.H.S.A. Division of Health
More informationLiquid-based cytology
Liquid-based cytology Claire Bourgain UZBrussel Introduction LBC for gynaecological cytology has been introduced in Belgium a decade ago There is no consensus On performance compared to conventional cytology
More informationUniversity of Saint Joseph College of Pharmacy
State School code Name of School AL 001 Auburn University AL 002 Samford University AR 004 University of Arkansas AR 096 Harding University AZ 003 University of Arizona AZ 082 Midwestern University-Glendale
More informationRates are valid through March 31, 2014.
The data in this chart was compiled from the physician fee schedule information posted on the CMS website as of January 2014. CPT codes and descriptions are copyright 2012 American Medical Association.
More informationANGELOUECONOMICS 2012 INDUSTRY HOTSPOTS
ANGELOUECONOMICS 2012 INDUSTRY HOTSPOTS INDUSTRY SPECIALIZATION OF AMERICA'S 100 LARGEST METROPOLITAN AREAS INDUSTRY CLUSTERS 19-24 (of 36) ABOUT THE RANKINGS In the 21 st Century, the engines that drive
More informationSophomore (30-60 semester hours or 45-90 quarter hours) Two-year Colleges Number of Students Tested at Each Institution July 2008 through June 2013
Number of Students Tested at Each Institution July 2008 through June 2013 List of Institutions Number of School Name Students AIKEN TECHNICAL COLLEGE, SC 169 ARKANSAS NORTHEASTERN COLLEGE, AR 84 ASHLAND
More informationLocal chapter Corporate partnership opportunities
2014 Local chapter Corporate partnership opportunities Making the American Dream a Reality for Those Who Have Served Us www.varep.net 2014 About VAREP Many real estate and financial service professionals
More informationTrends in Life Expectancy and Causes of Death Following Spinal Cord Injury. Michael J. DeVivo, Dr.P.H.
Trends in Life Expectancy and Causes of Death Following Spinal Cord Injury Michael J. DeVivo, Dr.P.H. Disclosure of PI-RRTC Grant James S. Krause, PhD, Holly Wise, PhD; PT, and Emily Johnson, MHA have
More informationHealth Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January June 2014
Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January June 04 by Michael E. Martinez, M.P.H., M.H.S.A., and Robin A. Cohen, Ph.D. Division of Health Interview
More informationAdditional information >>> HERE <<< Getting Free Instant Access freight broker training and job placement - Review
Additional information >>> HERE
More informationTreatment completion is an
Treatment Episode Data Set The TEDS Report Treatment Outcomes among Clients Discharged from Residential Substance Abuse Treatment: 2005 In Brief In 2005, clients discharged from shortterm were more likely
More informationPre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013
Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Objectives After completion of this presentation, the participant will be able to: Explain the current
More information2015 U.S. TOURISM QUALITY PERFORMANCE REPORT RESONANCE REPORT
2015 U.S. TOURISM QUALITY PERFORMANCE REPORT RESONANCE REPORT RESONANCE CONSULTANCY CREATES DEVELOPMENT STRATEGIES, PLANS, AND BRANDS THAT SHAPE THE FUTURE OF PLACES AROUND THE WORLD. Our team has advised
More informationU.S. Department of Housing and Urban Development: Weekly Progress Report on Recovery Act Spending
U.S. Department of Housing and Urban Development: Weekly Progress Report on Recovery Act Spending by State and Program Report as of 3/7/2011 5:40:51 PM HUD's Weekly Recovery Act Progress Report: AK Grants
More information2014-2015 Fact Sheet* Physical Therapist Assistant Education Programs October 2015
Last updated: //0 Contact: accreditation@apta.org 04-0 Fact Sheet* Physical Therapist Assistant Education Programs October 0 *This fact sheet is in-progress and will be updated with new data sets & charts
More information2016 Individual Exchange Premiums updated November 4, 2015
2016 Individual Exchange Premiums updated November 4, 2015 Within the document, you'll find insights across 50 states and DC with available findings (i.e., carrier participation, price leadership, gross
More informationMaking Sense of Your Pap and HPV Test Results
Making Sense of Your Pap and HPV Test Results Keep this booklet until you get your test results back from your doctor. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention
More information90-400 APPENDIX B. STATE AGENCY ADDRESSES FOR INTERSTATE UIB CLAIMS
INTERSTATE UIB CLAIMS Alabama Multi- Unit (#01) Industrial Relations Bldg. Montgomery, AL 31604 Alaska Interstate Unit (#02) P.O. Box 3-7000 Juneau, AK 99801 Arizona Interstate Liable Office (#03) Department
More informationIMMEDIATE HOT LINE: Effective March 2, 2015
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationForeign Language Enrollments in K 12 Public Schools: Are Students Prepared for a Global Society?
Foreign Language s in K 2 Public Schools: Are Students Prepared for a Global Society? Section I: Introduction Since 968, the American Council on the Teaching of Foreign Languages (ACTFL) has conducted
More informationEnrollment Snapshot of Radiography, Radiation Therapy and Nuclear Medicine Technology Programs 2014
Enrollment Snapshot of, Radiation Therapy and Nuclear Medicine Technology Programs 2014 January 2015 2015 ASRT. All rights reserved. Reproduction in any form is forbidden without written permission from
More informationUNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015 ANESTHESIOLOGY- 4 Beth Israel Deaconess Medical Center, Boston MA Oregon Health & Science University, Portland OR St. Louis Children s
More informationCultural Diversity May Be Increasing in Both Canada and the United States, But Important Differences Remain. By Dr. Doug Norris
Cultural Diversity May Be Increasing in Both Canada and the United By Dr. Doug Norris Table of Contents Introduction... 3 U.S. Cultural Diversity... 3 Table 1... 4 Table 2... 5 Cultural Diversity in Canada...
More informationUse and Characteristics of Electronic Health Record Systems Among Office-based Physician Practices: United States, 2001 2013
Use and Characteristics of Electronic Health Record Systems Among Office-based Physician Practices: United States, 2001 2013 Chun-Ju Hsiao, Ph.D., and Esther Hing, M.P.H. Key findings In 2013, 78% of office-based
More informationProfessional Liability Insurance Changes in Practice as a Result of the Affordability or Availability of Professional Liability Insurance
Overview of the 2015 ACOG Survey on Professional Liability By Andrea M. Carpentieri, MA, James J. Lumalcuri, MSW, Jennie Shaw, MPH, and Gerald F. Joseph, Jr., MD, FACOG The 2015 Survey on Professional
More informationSTATISTICAL BRIEF #173
Medical Expenditure Panel Survey STATISTICAL BRIEF #173 Agency for Healthcare Research and Quality June 27 Use of the Pap Test as a Cancer Screening Tool among Women Age 18 64, U.S. Noninstitutionalized
More informationANTHONY P. CARNEVALE NICOLE SMITH JEFF STROHL
State-Level Analysis HELP WANTED PROJECTIONS of JOBS and EDUCATION REQUIREMENTS Through 2018 JUNE 2010 ANTHONY P. CARNEVALE NICOLE SMITH JEFF STROHL Contents 1 Introduction 3 U.S. Maps: Educational concentrations
More informationAGGREGATE PROGRAM DATA
AGGREGATE PROGRAM DATA 2014 15 PHYSICAL THERAPIST EDUCATION PROGRAMS FACT SHEETS Beisner, Kathryn COMMISSION ON ACCREDITATION IN PHYSICAL THERAPY EDUCATION 1111 N. FAIRFAX ST. ALEXANDRIA, VA ACCREDITATION@APTA.ORG
More informationUniversity of Alabama School of Medicine 2016 Match Results by PGY1 Location
University of Alabama School of 206 Match Results by PGY Location Institution * City * State* Program * Count All Children s Hospital St. Petersburg FL Baptist Health System Birmingham AL General Surgery
More informationLICENSED SOCIAL WORKERS IN THE UNITED STATES, 2004 SUPPLEMENT. Chapter 2 of 5. Who Are Licensed Social Workers?
LICENSED SOCIAL WORKERS IN THE UNITED STATES, 2004 SUPPLEMENT Chapter 2 of 5 Who Are Licensed Social Workers? Prepared by Center for Health Workforce Studies School of Public Health, University at Albany
More informationHealth Workforce Data Collection: Findings from a Survey of States
Health Workforce Data Collection: Findings from a Survey of States Jean Moore, DrPH David Armstrong, PhD Health Workforce Technical Assistance Center School of Public Health University at Albany, SUNY
More informationINDEX ANNOUNCEMENT. July Rebalancing Results for S&P National AMT-Free Municipal Bond Index Announced by S&P Dow Jones Indices
INDEX ANNOUNCEMENT July Rebalancing Results for S&P National AMT-Free Municipal Bond Index Announced by S&P Dow Jones Indices New York, NY, June 27, 2016 S&P Dow Jones Indices announced today the results
More informationPreventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral
More informationITIL Foundation. Learn about process improvements, benefits, and challenges of ITIL, and get your ITIL Foundation certification.
ITIL Foundation Learn about process improvements, benefits, and challenges of ITIL, and get your ITIL Foundation certification. In this exciting and dynamic course, you will get an introduction to the
More informationEstimating college enrollment rates for Virginia public high school graduates
ISSUES& ANSWERS REL 2011 No. 104 Estimating college enrollment rates for Virginia public high school graduates ISSUES& ANSWERS REL 2011 No. 104 Estimating college enrollment rates for Virginia public high
More informationU.S. Department of Veterans Affairs: 2015 TCF List of Locations for VA Careers
U.S. Department of Veterans Affairs: 2015 TCF List of Locations for VA Careers How to Find Job Announcements and Apply VHA offers a designated number of TCF Program positions each year, for 2015 there
More informationDashboard. Campaign for Action. Welcome to the Future of Nursing:
Welcome to the Future of Nursing: Campaign for Action Dashboard About this Dashboard: These are graphic representations of measurable goals that the Campaign has selected to evaluate our efforts in support
More informationCervical Screening Programme
Cervical Screening Programme England 2010-11 1 The NHS Information Centre is England s central, authoritative source of health and social care information. Acting as a hub for high quality, national, comparative
More informationHealth Insurance Coverage of Children Under Age 19: 2008 and 2009
Health Insurance Coverage of Children Under Age 19: 2008 and 2009 American Community Survey Briefs Issued September 2010 ACSBR/09-11 IntroductIon Health insurance, whether private or public, improves children
More informationPhysical Therapy Marketing Success :: physical therapy assistant schools usa
Physical Therapy Marketing Success :: physical therapy assistant schools usa Physical Therapy Marketing Success :: physical therapy assistant schools usa Downloading From Original Website --> http://f-ebook.esy.es/ptsuccess/pdx/fph1
More information